Free Trial
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:COGT

Cogent Biosciences Q3 2026 Earnings Date & Estimates

Cogent Biosciences logo
$31.00 +0.92 (+3.06%)
Closing price 04:00 PM Eastern
Extended Trading
$31.01 +0.01 (+0.03%)
As of 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cogent Biosciences is expected to report Q3 2026 earnings on Friday, November 6, 2026, before market opens. The conference call is scheduled for November 2, 2026 at 12:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call Date
Conference Call
12:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Cogent Biosciences in Q3 2026

Cogent Biosciences is expected to post earnings of -$0.57 per share on revenue of $0.75 million. In the same quarter a year earlier Cogent Biosciences reported -$0.50 per share. Cogent Biosciences last reported on August 10, 2026, posting -$0.52 per share and beating the -$0.5550 consensus estimate. Cogent Biosciences has beaten the consensus EPS estimate in 5 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.57
Expected Revenue
$0.75 million
Prior-Year EPS
-$0.50

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.52 (Beat by +$0.0350)
EPS Beat Rate
5 of last 8 quarters

Prepare for the Q3 2026 Call

Cogent Biosciences Q3 2026 Earnings FAQ

Cogent Biosciences (NASDAQ:COGT) is estimated to report Q3 2026 earnings on Friday, November 6, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Cogent Biosciences' Q3 2026 earnings conference call is scheduled for Monday, November 2, 2026 at 12:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Cogent Biosciences to post earnings of -$0.57 per share for Q3 2026.

The consensus revenue estimate for Cogent Biosciences is $0.75 million for Q3 2026.

Cogent Biosciences Earnings Headlines

Cogent Biosciences, Inc. (NASDAQ:COGT) Stock Has Average Target Price of $51.56 According to Analysts
October 1, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31073190
Cogent Biosciences (COGT) Stock Trades At A Premium As FDA Accepts NDA
September 25, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/cogent-biosciences-cogt-stock-trades-101007883.html
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.tc pixel
October 9 at 1:00 AM  |  Stansberry Research (Ad)
Will FDA’s Streamlined Bezuclastinib Review in ASM Change Cogent Biosciences’ (COGT) Narrative?
September 24, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/fda-streamlined-bezuclastinib-review-asm-121136546.html
Cogent Biosciences (COGT) Looks Fully Valued Following FDA NDA Acceptance
September 24, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/cogent-biosciences-cogt-looks-fully-181215815.html
Cogent's Bezuclastinib NDA Accepted For Advanced Systemic Mastocytosis; PDUFA Set For June 2027
September 15, 2026  |  rttnews.comhttps://www.rttnews.com/3691192/cogent-s-bezuclastinib-nda-accepted-for-advanced-systemic-mastocytosis-pdufa-set-for-june-2027.aspx
See More Cogent Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cogent Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cogent Biosciences and other key companies, straight to your email.

About Cogent Biosciences

Cogent Biosciences (NASDAQ:COGT) is a clinical-stage biotechnology company focused on developing precision therapies for genetically defined diseases. The company’s research programs are designed to selectively target disease-driving proteins while minimizing effects on healthy cells.

Cogent’s lead product candidate is bezuclastinib, also known as CGT948, an oral, highly selective inhibitor of the KIT D816V mutation and other KIT alterations. The company is evaluating bezuclastinib in systemic mastocytosis, a disorder involving the abnormal growth and accumulation of mast cells, as well as in gastrointestinal stromal tumors (GIST) and other KIT-driven diseases.

Cogent conducts research and clinical development activities in the United States and works with healthcare professionals, patients and research institutions through its clinical programs. The company is headquartered in Boulder, Colorado, and is led by Andrew Robbins, who serves as president and chief executive officer.

View Cogent Biosciences Profile
Earnings Tools